

Cytidine Deaminase Inhibitors (CDA) - Pipeline Insight, 2022

<https://marketpublishers.com/r/C5CBC73032C2EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: C5CBC73032C2EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Cytidine Deaminase Inhibitors (CDA) - Pipeline Insight, 2022" report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Cytidine Deaminase Inhibitors (CDA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Cytidine Deaminase Inhibitors (CDA) Understanding

Cytidine Deaminase Inhibitors (CDA): Overview

Cytidine deaminase inhibitors are molecules that inhibit the activity of the enzyme cytidine deaminase. Cytidine deaminase is an evolutionarily conserved enzyme of the pyrimidine salvage pathway. It catalyzes the hydrolytic deamination of cytidine and deoxycytidine to form uridine and deoxyuridine, respectively. Human cytidine deaminase (CDA) is an enzyme prominent for its role in catalyzing metabolic processing of nucleoside-type anticancer and antiviral agents. It is thus a promising target for the development of small molecule therapeutic adjuvants. Cytidine deaminase inhibitors are considered as a potential and promising treatment for tumors with highly expressed

CDA.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cytidine Deaminase Inhibitors (CDA) R&D. The therapies under development are focused on novel approaches for Cytidine Deaminase Inhibitors (CDA).

Cytidine Deaminase Inhibitors (CDA) Emerging Drugs Chapters

This segment of the Cytidine Deaminase Inhibitors (CDA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cytidine Deaminase Inhibitors (CDA) Emerging Drugs

ASTX727: Astex Pharmaceuticals

ASTX727 is a novel, orally administered fixed dose combination of cedazuridine, an inhibitor of cytidine deaminase, with the anti-cancer DNA hypomethylating agent, decitabine. By inhibiting cytidine deaminase, cedazuridine inhibits the major mechanism by which decitabine is degraded in the gut and liver, and the combination therefore permits the efficient delivery of decitabine orally.

Further product details are provided in the report.....

Cytidine Deaminase Inhibitors (CDA): Therapeutic Assessment

This segment of the report provides insights about the different Cytidine Deaminase Inhibitors (CDA) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Cytidine Deaminase Inhibitors (CDA)

There are approx. 2+ key companies which are developing the Cytidine Deaminase Inhibitors (CDA). The companies which have their Cytidine Deaminase Inhibitors (CDA) drug candidates in the most advanced stage, i.e. Phase III include, Astex Pharmaceuticals.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cytidine Deaminase Inhibitors (CDA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cytidine Deaminase Inhibitors (CDA): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cytidine Deaminase Inhibitors (CDA) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytidine Deaminase Inhibitors (CDA) drugs.

Cytidine Deaminase Inhibitors (CDA) Report Insights

Cytidine Deaminase Inhibitors (CDA) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Cytidine Deaminase Inhibitors (CDA) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Cytidine Deaminase Inhibitors (CDA) drugs?

How many Cytidine Deaminase Inhibitors (CDA) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Cytidine Deaminase Inhibitors (CDA)?

What are the key collaborations (Industry–Industry, Industry–Academia),

Mergers and acquisitions, licensing activities related to the Cytidine Deaminase Inhibitors (CDA) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cytidine Deaminase Inhibitors (CDA) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Astex Pharmaceuticals

Novo Nordisk

Key Products

ASTX727

Decitabine/tetrahydrouridine

ASTX-030

Contents

Introduction

Executive Summary

Cytidine Deaminase Inhibitors (CDA): Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Cytidine Deaminase Inhibitors (CDA) – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Cytidine Deaminase Inhibitors (CDA) companies' collaborations, Licensing,
Acquisition -Deal Value Trends

Cytidine Deaminase Inhibitors (CDA) Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Registered)

Comparative Analysis

ASTX727: Astex Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

ASTX-030: Astex Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Cytidine Deaminase Inhibitors (CDA) Key Companies

Cytidine Deaminase Inhibitors (CDA) Key Products

Cytidine Deaminase Inhibitors (CDA)- Unmet Needs

Cytidine Deaminase Inhibitors (CDA)- Market Drivers and Barriers

Cytidine Deaminase Inhibitors (CDA)- Future Perspectives and Conclusion

Cytidine Deaminase Inhibitors (CDA) Analyst Views

Cytidine Deaminase Inhibitors (CDA) Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Cytidine Deaminase Inhibitors (CDA)

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Cytidine Deaminase Inhibitors (CDA)

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Cytidine Deaminase Inhibitors (CDA) - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/C5CBC73032C2EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5CBC73032C2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970